Department of Laboratory Medicine, Section for Clinical Immunology and Transfusion Medicine, Örebro University Hospital, 70185, Örebro, Sweden.
Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Sci Rep. 2022 Aug 30;12(1):14762. doi: 10.1038/s41598-022-18972-5.
The soluble tumor necrosis factor receptors (sTNFR1 and sTNFR2) are suggested to play dual roles on physiological and pathophysiological actions of TNF-α. The aim of this study was to investigate the dynamic changes of these biomarkers in patients with ST-segment elevation myocardial infarction (STEMI). Blood was collected from 165 STEMI patients at admission, 1-3 days and 3 months after percutaneous coronary intervention (PCI) and from 40 healthy blood donors. sTNFR1 and sTNFR2 were measured with ELISA. The plasma levels of both sTNFR1 and sTNFR2 were significantly higher than in healthy donors at all three time points. We found no significant differences in sTNFR1 or sTNFR2 when comparing patients with patent versus occluded culprit vessels, or between patients having a thrombus aspiration or not. Survival analysis was performed comparing patients with levels of biomarkers above and below the median values at that time point. We found significant differences in survival for sTNFR2 in acute samples (p = 0.0151) and for both sTNFR1 and sTNFR2 in samples 1-3 days after PCI (p = 0.0054 and p = 0.0003, respectively). Survival analyses suggest that sTNFR1 or sTNFR2 could be promising markers to predict mortality in STEMI patients after PCI.
可溶性肿瘤坏死因子受体（sTNFR1 和 sTNFR2）被认为在 TNF-α 的生理和病理生理作用中发挥双重作用。本研究旨在探讨这些生物标志物在 ST 段抬高型心肌梗死（STEMI）患者中的动态变化。从 165 例经皮冠状动脉介入治疗（PCI）入院、1-3 天和 3 个月的 STEMI 患者以及 40 名健康献血者中采集血液。采用 ELISA 法检测 sTNFR1 和 sTNFR2。在所有三个时间点，sTNFR1 和 sTNFR2 的血浆水平均明显高于健康供体。我们发现，比较罪犯血管通畅和闭塞的患者、或比较进行血栓抽吸和未进行血栓抽吸的患者，sTNFR1 或 sTNFR2 无显著差异。比较当时点生物标志物水平高于和低于中位数的患者的生存分析。我们发现，sTNFR2 在急性样本中（p=0.0151），sTNFR1 和 sTNFR2 在 PCI 后 1-3 天的样本中（p=0.0054 和 p=0.0003）的生存差异有统计学意义。生存分析表明，sTNFR1 或 sTNFR2 可能是预测 STEMI 患者 PCI 后死亡率的有前途的标志物。
